Page last updated: 2024-12-08
patrinoside
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
patrinoside: obtained from Patrina scabiosaefolia; RN given refers to (1S-(1 alpha,4a alpha,6 alpha,7 alpha,7a alpha))-isomer; structure in 9th CI Form Index [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 162135 |
| CHEBI ID | 7941 |
| MeSH ID | M0052920 |
Synonyms (13)
| Synonym |
|---|
| beta-d-glucopyranoside, (1,4a,5,6,7,7a-hexahydro-6-hydroxy-7-(hydroxymethyl)-1-(3-methyl-1-oxobutoxy)cyclopenta(c)pyran-4-yl)methyl, (1s-(1-alpha,4a-alpha,6-alpha,7-alpha,7a-alpha))- |
| 53962-20-2 |
| patrinoside |
| [(1s,4as,6s,7s,7as)-6-hydroxy-7-(hydroxymethyl)-4-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-1-yl] 3-methylbutanoate |
| 59436l0ys2 , |
| unii-59436l0ys2 |
| CHEBI:7941 |
| .beta.-d-glucopyranoside, ((1s,4as,6s,7s,7as)-1,4a,5,6,7,7a-hexahydro-6-hydroxy-7-(hydroxymethyl)-1-(3-methyl-1-oxobutoxy)cyclopenta(c)pyran-4-yl)methyl |
| .beta.-d-glucopyranoside, (1,4a,5,6,7,7a-hexahydro-6-hydroxy-7-(hydroxymethyl)-1-(3-methyl-1-oxobutoxy)cyclopenta(c)pyran-4-yl)methyl, (1s-(1.alpha.,4a.alpha.,6.alpha.,7.alpha.,7a.alpha.))- |
| ((1s,4as,6s,7s,7as)-1,4a,5,6,7,7a-hexahydro-6-hydroxy-7-(hydroxymethyl)-1-(3-methyl-1-oxobutoxy)cyclopenta(c)pyran-4-yl)methyl .beta.-d-glucopyranoside |
| Q27107631 |
| DTXSID20968774 |
| 4-[(hexopyranosyloxy)methyl]-6-hydroxy-7-(hydroxymethyl)-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-1-yl 3-methylbutanoate |
Research Excerpts
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| terpene glycoside | A terpenoid in which one or more hydroxy functions are glycosylated. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (57.14) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||